

Kazia Therapeutics Ltd (KZA) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/K03BC6CA05FEN.html>

Date: October 2021

Pages: 38

Price: US\$ 125.00 (Single User License)

ID: K03BC6CA05FEN

Abstracts

Kazia Therapeutics Ltd (KZA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kazia Therapeutics Ltd (Kazia) is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. The company's product pipeline includes paxalisib (formerly GDC-0084) and Cantrixil (TRX-E-002-1). Paxalisib is an inhibitor of PI3K /AKT /mTOR pathway to treat glioblastoma multiforme It is in phase II clinical trials. TRX-E-002-1 (Cantrixil) is a third generation benzopyran molecule which acts against cancer stem cells. Cantrixil is in phase I clinical trials for the treatment of ovarian cancer. The company has collaborations with various research institutes, hospitals, universities including St Jude Children's Hospital, University of Newcastle, Dana Farber Cancer Institute and Memorial Sloan Kettering Cancer Centre to develop its pipeline. Kazia is headquartered in Sydney, New South Wales, Australia.

Kazia Therapeutics Ltd Key Recent Developments

Dec 14,2020: Kazia receives 1.02 million R&D cash rebate

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential

customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Kazia Therapeutics Ltd - Key Facts
Kazia Therapeutics Ltd - Key Employees
Kazia Therapeutics Ltd - Key Employee Biographies
Kazia Therapeutics Ltd - Major Products and Services
Kazia Therapeutics Ltd - History
Kazia Therapeutics Ltd - Company Statement
Kazia Therapeutics Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Kazia Therapeutics Ltd - Business Description
Kazia Therapeutics Ltd - SWOT Analysis
SWOT Analysis - Overview
Kazia Therapeutics Ltd - Strengths
Kazia Therapeutics Ltd - Weaknesses
Kazia Therapeutics Ltd - Opportunities
Kazia Therapeutics Ltd - Threats
Kazia Therapeutics Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD
2021

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD
2021

Kazia Therapeutics Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Dec 14, 2020: Kazia receives 1.02 million R&D cash rebate

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Kazia Therapeutics Ltd, Key Facts
Kazia Therapeutics Ltd, Key Employees
Kazia Therapeutics Ltd, Key Employee Biographies
Kazia Therapeutics Ltd, Major Products and Services
Kazia Therapeutics Ltd, History
Kazia Therapeutics Ltd, Subsidiaries
Kazia Therapeutics Ltd, Key Competitors
Kazia Therapeutics Ltd, Ratios based on current share price
Kazia Therapeutics Ltd, Annual Ratios
Kazia Therapeutics Ltd, Annual Ratios (Cont...1)
Kazia Therapeutics Ltd, Interim Ratios
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Kazia Therapeutics Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Kazia Therapeutics Ltd, Performance Chart (2017 - 2021)

Kazia Therapeutics Ltd, Ratio Charts

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD
2021

Kazia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD
2021

I would like to order

Product name: Kazia Therapeutics Ltd (KZA) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/K03BC6CA05FEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/K03BC6CA05FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970